Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 372

Sort by

Sort Order Select

Journal Articles

Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)

Veronica A Guerra, MD, Jan A. Burger, MD PhD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 567.

https://doi.org/10.1182/blood-2019-125970

Published: 2019

Journal Articles

Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD

Pamela Allen, MD MSc, Hatice Savas, MD, Andrew M. Evens, DO,MSc, Barbara Pro, MD, Reem Karmali, MD, Brett Alan Palmer, BS, Eric Mou, MD, Jeffrey Bearden, BA, Denise M Scholtens, PhD, Gary Dillehay, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 235.

https://doi.org/10.1182/blood-2019-123906

Published: 2019

Journal Articles

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Brian T. Hill, MD, Shuo Ma, MD PhD, Andrea M Baran, MS, Andrew Bui, Philip J Meacham, MS, Ashley Morrison, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S Weiss, Jonathan W. Friedberg, MD, Clive S Zent, MD

Blood (2019) 134 (Supplement_1): 360.

https://doi.org/10.1182/blood-2019-123404

Published: 2019

Journal Articles

Deviation from Guidelines in Use of Eltrombopag and Romiplostim in Clinical Practice for Children with Primary Immune Thrombocytopenia; Multi-Center Egyptian Experience

Mohsen Saleh Elalfy, MD, Tamer Hassan, MD, Khalid Elsayh, MD, Mohamed Maebid, MD, Hoda Hassab, MD, Rasha Elashry, MD, Mona El ghamrawy, MD, Mahmoud Elhawy, MD, Marwa Zakaria, MD, Mohamed Elshanshory, MD

Blood (2019) 134 (Supplement_1): 4907.

https://doi.org/10.1182/blood-2019-121994

Published: 2019

Journal Articles

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Blood (2019) 134 (Supplement_1): 5249.

https://doi.org/10.1182/blood-2019-125921

Published: 2019

Journal Articles

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

James K. Mangan, MD PhD, Imran Ajmal, MBBS, Noelle V. Frey, MD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, Martin Carroll, MD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 5155.

https://doi.org/10.1182/blood-2019-131668

Published: 2019

Journal Articles

Pegasperagase Toxicity in Adult Patients with Acute Lymphoblastic Leukemia: A Single Center Experience Comparing Patients Older and Younger Than 35 Years of Age

Jun H Choi, MD, Jacques Azzi, MD, Tsivia Hochman, MS, Mary Lynn R. Nierodzik, MD, Shella Saint Fleur-Lominy, MD PhD, Maher Abdul Hay, MD

Blood (2019) 134 (Supplement_1): 5067.

https://doi.org/10.1182/blood-2019-129041

Published: 2019

Journal Articles

Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study

Blood (2019) 134 (Supplement_1): 5476.

https://doi.org/10.1182/blood-2019-126402

Published: 2019

Journal Articles

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Blood (2019) 134 (Supplement_1): 5320.

https://doi.org/10.1182/blood-2019-124102

Published: 2019

Journal Articles

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Eric Huselton, MD, Amanda F Cashen, MD, John F. DiPersio, MD PhD, Meagan Jacoby, MD, Iskra Pusic, MD, Rizwan Romee, MD PhD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD

Blood (2019) 134 (Supplement_1): 3915.

https://doi.org/10.1182/blood-2019-132065

Published: 2019

Journal Articles

Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Franco Locatelli, MD, Gerhard Zugmaier, Peter Bader, MD, Sima Jeha, MD, Paul-Gerhardt Schlegel, Jean-Pierre Bourquin, MD PhD, Rupert Handgretinger, MD, Benoit Brethon, MD, Claudia Rossig, Christiane Chen-Santel

Blood (2019) 134 (Supplement_1): 1294.

https://doi.org/10.1182/blood-2019-121615

Published: 2019

Journal Articles

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma

Loretta J. Nastoupil, MD MSc, Sattva S Neelapu, MD, Eric Davis, MD, Felipe Samaniego, MD, Nathan H Fowler, MD, Jason R. Westin, MD, Hun Ju Lee, Michael Wang, MD, Fredrick B. Hagemeister, MD, Philip Beer, MD PhD, Alexander R. L. Cecil, James Dow, Duncan McHale, Franck Silva, Penny Ward, Arash Yavari, Stephen Joseph Shuttleworth, PhD

Blood (2019) 134 (Supplement_1): 4099.

https://doi.org/10.1182/blood-2019-130401

Published: 2019

Journal Articles

Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort

Tarsheen Sethi, MD MBBS, Alexandra E. Kovach, MD, Emily F Mason, MD PhD, Heidi Chen, PhD, Tamara Moyo, MD PhD, Olalekan O. Oluwole, MBBS, MPH, David Morgan, MD, Nishitha Reddy, MD

Blood (2019) 134 (Supplement_1): 4100.

https://doi.org/10.1182/blood-2019-129634

Published: 2019

Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 3892.

https://doi.org/10.1182/blood-2019-126009

Published: 2019

Journal Articles

Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Patients from the Learn Consortium

Joanna S. Yi, MD, Tiffany Chambers, MPH, Kelly D Getz, Tamara P. Miller, MDMSc, Evanette Burrows, MPH, Marla Daves, MD, Philip J. Lupo, PhD MPH, Michael E. Scheurer, PhD MPH, Richard Aplenc, MD PhD, Karen R. Rabin, MD PhD, Maria Monica J. Gramatges, MD PhD

Blood (2019) 134 (Supplement_1): 3814.

https://doi.org/10.1182/blood-2019-123992

Published: 2019

Journal Articles

Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic Leukemia

Ryan J. Daley, PharmD, Sridevi Rajeeve, MD, Charlene C. Kabel, PharmD, Jeremy J. Pappacena, PharmD, BCOP, Sarah E. Stump, PharmD, BCPS, BCOP, Jessica A. Lavery, MS, Martin S. Tallman, MD, Mark B. Geyer, MD, Jae H. Park, MD

Blood (2019) 134 (Supplement_1): 3816.

https://doi.org/10.1182/blood-2019-124727

Published: 2019

Journal Articles

Single Arm, Single Centre Prospective Study to Assess the Effect of Therapeutic Drug Monitoring (TDM) Based Dosage Adjustment of Posaconazole on the Incidence of Invasive Fungal Infections (IFIs) in AML Patients on Induction Chemotherapy on Posaconazole Prophylaxis

Manju Sengar, MD DM, Mounika Boppana, MD DM, Hasmukh Jain, MD DM, Vikram Gota, MD, Bhausaheb Bagal, MD DM, Anant Gokarn, MD, Murari Gujrar, MD, Madhavi Ambotkar, MD

Blood (2019) 134 (Supplement_1): 2600.

https://doi.org/10.1182/blood-2019-129948

Published: 2019

Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2325.

https://doi.org/10.1182/blood-2019-124176

Published: 2019

Journal Articles

Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy Backbone

Swapna Thota, MD, Abhay Singh, MBBS,MPH, Sarah Sadek, MD, Mark G. Faber, DO, Jeffrey Baron, PharmD, Amro Elshoury, MBBChir, James E. Thompson, MD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 2645.

https://doi.org/10.1182/blood-2019-131633

Published: 2019

Journal Articles

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Sudipto Mukherjee, MD PhD MPH, Hong Li, Brian P. Hobbs, PhD, Aaron T. Gerds, MD MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Aziz Nazha, MD, Samjhana Bogati, RN, Eric Parsons, RN, Benjamin Pannell, Matt Kalaycio, MD, Yogenthiran Saunthararajah, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 2595.

https://doi.org/10.1182/blood-2019-132178

Published: 2019

NARROW

Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)

Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Deviation from Guidelines in Use of Eltrombopag and Romiplostim in Clinical Practice for Children with Primary Immune Thrombocytopenia; Multi-Center Egyptian Experience

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

Pegasperagase Toxicity in Adult Patients with Acute Lymphoblastic Leukemia: A Single Center Experience Comparing Patients Older and Younger Than 35 Years of Age

Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma

Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Patients from the Learn Consortium

Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic Leukemia

Single Arm, Single Centre Prospective Study to Assess the Effect of Therapeutic Drug Monitoring (TDM) Based Dosage Adjustment of Posaconazole on the Incidence of Invasive Fungal Infections (IFIs) in AML Patients on Induction Chemotherapy on Posaconazole Prophylaxis

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy Backbone

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only